The AAA+ chaperone VCP disaggregates Tau fibrils and generates aggregate seeds

Itika Saha^{1,2}, Patricia Yuste-Checa^{1,2}, Miguel Da Silva Padilha^{3,4}, Qiang Guo^{5,#}, Roman Körner¹,
Hauke Holthusen¹, Victoria A. Trinkaus^{1,5,6}, Irina Dudanova^{3,4}, Rubén Fernández-
Busnadiego^{2,5,7,8}, Wolfgang Baumeister⁵, David W. Sanders^{9,‡}, Saurabh Gautam^{1,§}, Marc I.
Diamond⁹, F. Ulrich Hartl^{1,2,6,*} and Mark S. Hipp^{1,6,10,11*}

¹Department of Cellular Biochemistry, Max Planck Institute of Biochemistry, Am Klopferspitz
18, 82152 Martinsried, Germany.

²Aligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase,
MD, USA.

³Molecular Neurodegeneration Group, Max Planck Institute of Neurobiology,
82152 Martinsried, Germany.

⁴Department of Molecules – Signaling – Development, Max Planck Institute of Neurobiology,
Am Klopferspitz 18, 82152 Martinsried, Germany.

⁵Department of Structural Molecular Biology, Max Planck Institute of Biochemistry, Am
Klopferspitz 18, 82152 Martinsried, Germany.

⁶Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.

⁷Institute of Neuropathology, University Medical Center Göttingen, 37099 Göttingen, Germany.

⁸Cluster of Excellence “Multiscale Bioimaging: from Molecular Machines to Networks of
Excitable Cells” (MBExC), University of Göttingen, Germany.

⁹Center for Alzheimer's and Neurodegenerative Diseases, Peter O'Donnell Jr. Brain Institute,
University of Texas Southwestern Medical Center, Dallas, 75390 Texas, USA.

¹⁰School of Medicine and Health Sciences, Carl von Ossietzky University Oldenburg,
Oldenburg, Germany.

¹¹Department of Biomedical Sciences of Cells and Systems, University Medical Center
Groningen, University of Groningen, Antonius Deusinglaan, 1, 9713 AV Groningen, The
Netherlands.

Present address: State Key Laboratory of Protein and Plant Gene Research, School of Life
Sciences and Peking-Tsinghua Center for Life Sciences, Peking University, Beijing 100871,
China.

‡ Present address: Department of Chemical and Biological Engineering, Princeton University,
Princeton, NJ 08544, USA

§ Present address: Boehringer Ingelheim International GmbH, 55216 Ingelheim, Germany and
ViraTherapeutics GmbH, 6063 Rum, Austria.

* To whom correspondence should be addressed:

uhartl@biochem.mpg.de (FUH); m.s.hipp@umcg.nl (MSH)

Abstract

Amyloid-like aggregates of the microtubule-associated protein Tau are associated with several neurodegenerative disorders including Alzheimer's disease. The existence of cellular machinery for the removal of such aggregates has remained unclear, as specialized disaggregase chaperones are thought to be absent in mammalian cells. Here we show in cell culture and in neurons that the AAA+ chaperone VCP is recruited to ubiquitylated Tau fibrils, resulting in their efficient disaggregation. Aggregate clearance depends on the functional cooperation of VCP with Hsp70 and the ubiquitin-proteasome machinery. Inhibition of VCP activity stabilizes large Tau aggregates, and is accompanied by a reduction in the amount of Tau species competent of prion-like aggregate seeding in recipient cells. Thus, disaggregation by VCP generates seeding-active Tau as byproduct. These findings identify VCP as a core component of the machinery for the removal of neurodegenerative disease aggregates and suggest that its activity can be associated with enhanced aggregate spreading in tauopathies.

Introduction

Deposition of amyloid-like Tau aggregates is a hallmark of devastating neurodegenerative disorders such as Alzheimer's disease and frontotemporal dementia¹. In healthy neurons, Tau functions in microtubule (MT) assembly and stabilization by associating with MTs via its repeat domain (RD) consisting of three or four 31-32 residue imperfect repeats. Two hexapeptide motifs within the RD are critical for Tau aggregation, and the RD forms the structural core of disease-associated aggregates¹, with several RD mutations underlying familial tauopathies². Expression of human Tau mutants in mouse models recapitulates essential features of

tauopathies including the formation of amyloid-like Tau deposits and neuronal loss^{3,4}, indicating that Tau aggregation is central to neurodegeneration. Pathogenic Tau aggregates often exhibit the ability to induce aggregation in naïve cells through a mechanism of transcellular propagation that allows aggregate pathology to spread across brain regions^{5,6}. Notably, pathological Tau aggregates and spreading are resolved upon lowering Tau levels, which is accompanied by improved neuronal health and extended lifespan^{7,8}. However, the cellular mechanisms involved in the reversal, clearance and spread of Tau aggregates remain poorly understood.

While specialized chaperones of the AAA+ family in bacteria, yeast and plants have the ability to resolve amyloid-like aggregates^{9,10}, direct homologues of these hexameric disaggregases have not been identified in mammalian cells. Instead, disaggregation in higher eukaryotes is mainly attributed to the Hsp70 chaperone machinery¹¹⁻¹⁴. The human Hsp70-Hsp40-Hsp110 chaperone system efficiently dissociates Tau and α -synuclein fibrils in vitro¹⁵⁻¹⁷ independent of AAA+ disaggregases that cooperate with the Hsp70 system in yeast and bacteria to achieve disaggregation⁹. The eukaryotic AAA+ ATPase valosin-containing protein (VCP) exerts ATP-dependent protein unfolding activity^{18,19} and has been proposed to resolve protein aggregates^{20,21} and certain condensates such as stress granules^{22,23}. VCP facilitates protein turnover via the ubiquitin-proteasome system^{24,25}, in addition to sustaining functional autophagy²⁶. Indeed, VCP mutations have been associated with aggregate deposition disorders such as vacuolar tauopathy and inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia (IBMPFD)^{20,27-29}. Accumulation of Tau aggregates in vacuolar tauopathy was proposed to be a consequence of diminished ATPase activity of mutant VCP (D395G)²⁰. IBMPFD-associated VCP mutants exhibit increased basal ATP hydrolysis and unfolding activity^{30,31}, altered interactions with cofactors^{32,33} and perturbed autophagic

function³⁴. Whether any of these mutations influence the clearance of pre-formed fibrillar Tau aggregates in cells is not known.

Here we provide direct evidence in a cell culture model and in primary murine neurons that VCP disaggregates amyloid-like Tau fibrils in a ubiquitin and proteasome-dependent manner, with the Hsp70 chaperone system contributing to aggregate clearance. This function of VCP is not detectably perturbed by pathogenic VCP mutations. Although disaggregation by VCP is coupled to proteasomal degradation, intermediates of the disaggregation process escape proteolysis and are a source of seeding-competent Tau species.

Results

To investigate the ability of cells to clear Tau aggregates, we used HEK293 cells stably expressing TauRD-Y (P301L/V337M), a mutant of the amyloid-forming repeat domain of Tau^{35,36} fused to YFP via a flexible linker³⁷ (Fig. 1a). TauRD-Y is soluble and diffusely distributed in TauRD-Y cells, but the extracellular addition of Tau aggregates isolated from tauopathy brain tissue or generated in vitro induces its aggregation via template-based seeding, leading to formation of aggregates that are stably propagated for weeks^{37,38} (Fig. 1b). Using TauRD-Y aggregate seeds³⁷, we generated a cell line (TauRD-Y*) in which phosphorylated TauRD-Y accumulated in cytosolic inclusions 0.5-5 μm^2 in size that stained with the amyloid-specific dye Amylo-Glo³⁹ (Fig. 1c, Supplementary Fig. 1a-c). Analysis of the inclusions in intact TauRD-Y* cells by cryo-electron tomography revealed TauRD-Y fibrils of ~18 nm diameter, which were distinguishable from cytoskeletal structures (Fig. 1d) and consistent with the structures of fibrillar Tau in tauopathy patient brain⁴⁰⁻⁴⁴. Thus, TauRD forms amyloid-like

fibrillar aggregates in TauRD-Y* cells. TauRD-Y aggregates were also able to induce aggregates of full-length Tau fused to YFP (FLTau-Y). These aggregates reacted with the AT-8 antibody specific for phosphorylation at serine 202 and threonine 205 (epitopes not present in TauRD) (Fig. 1a, Supplementary Fig. 1d,e), which has been used previously to detect paired helical filaments^{45,46}.

Proteasomal clearance of Tau aggregates

Soluble TauRD-Y was efficiently degraded in TauRD-Y cells upon inhibition of protein synthesis with cycloheximide (CHX) (Supplementary Fig. 1f). CHX treatment also led to partial clearance of TauRD inclusions in TauRD-Y* cells (Fig. 1e, Supplementary Fig. 1f,g). To avoid global inhibition of protein synthesis, we employed cells in which the expression of TauRD-Y is controlled with a Tet-regulated promoter (Tet-TauRD-Y and Tet-TauRD-Y* cells)³⁷ (Supplementary Fig. 2a). Addition of doxycycline resulted in clearance of TauRD-Y inclusions and insoluble TauRD-Y protein ($t_{1/2} \sim 12$ h) (Supplementary Fig. 2a-d). The amount of insoluble TauRD-Y decreased faster than the level of soluble TauRD-Y (Supplementary Fig. 2d), consistent with aggregate material being solubilized prior to degradation. Moreover, inhibition of TauRD-Y synthesis resulted in a time dependent reduction of inclusion size and number per cell (Fig. 1f). Thus, the cells are able to efficiently dissociate and degrade amyloid-like TauRD-Y aggregates.

Addition of the selective proteasome inhibitor Epoxomicin or siRNA-mediated downregulation of the proteasome component PSMD11 stabilized aggregated TauRD-Y upon doxycycline shut-off and prevented aggregate clearance (Supplementary Fig. 3a-e). Proteasome inhibition also stabilized soluble TauRD-Y in Tet-TauRD-Y cells⁴⁷ (Supplementary Fig. 3a), but

did not lead to de novo Tau aggregation⁴⁸ (Supplementary Fig. 4h). Hence, the persistence of TauRD-Y aggregates upon proteasome inhibition is due to stabilization of pre-existing aggregates. In contrast, inhibition of lysosomal degradation with Bafilomycin A1 (confirmed by increased levels of LC3-II) or of autophagy with 3-methyladenine was without effect on the levels of total or aggregated TauRD-Y protein in the cellular model used (Supplementary Fig. 3a-c). Downregulation of autophagy components ATG5/7 supported this conclusion (Supplementary Fig. 3d,e). Thus, TauRD-Y aggregates are degraded in a proteasome-dependent, autophagy-independent manner.

Tau disaggregation requires VCP

Proteins must generally be unfolded to access the catalytic center of the 20S proteasome. Thus, prior to degradation, aggregated proteins need to undergo disaggregation⁴⁹. To identify the cellular machinery involved in TauRD-Y disaggregation, we performed an interactome analysis of aggregated TauRD-Y by quantitative mass spectrometry. We identified the AAA+ ATPase VCP as one of the most highly enriched interactors of aggregated TauRD-Y, along with the ubiquitin-binding VCP cofactors UFD1L, NPLOC4 and NSFL1C, and multiple subunits of the 26S proteasome (Fig. 2a, Supplementary Table 1). Hsp70 was detected in the proteomic analysis but was not enriched on aggregated TauRD-Y. Co-localization of VCP and its cofactors with TauRD-Y aggregates was confirmed by fluorescence microscopy (Fig. 2b, Supplementary Fig. 4a-c).

VCP utilizes the energy from ATP hydrolysis to structurally remodel and unfold proteins in different cellular contexts^{18,50}. To assess whether VCP is involved in TauRD-Y disaggregation, we inhibited VCP in cells using NMS-873, a small molecule allosteric inhibitor

of the VCP ATPase⁵¹. Similar to proteasome inhibition, NMS-873 blocked the clearance of TauRD-Y aggregates when TauRD-Y synthesis was stopped with doxycycline (Fig. 2c,d). Likewise, the aggregates were stabilized when VCP was inhibited using CB-5083 (Supplementary Fig. 4d), a competitive inhibitor of ATP binding in the D2 ATPase domain of VCP⁵², or down-regulated with siRNA (Supplementary Fig. 4e,f). VCP inhibition during ongoing TauRD-Y synthesis resulted in a significant increase in inclusion size (Supplementary Fig. 4g), suggesting that the inclusions exist at a dynamic equilibrium between formation and disaggregation. No aggregation of soluble TauRD-Y was detected after treating cells with NMS-873 or VCP siRNA (Supplementary Fig. 4 h,i). VCP down-regulation caused a marginal increase in the level of soluble TauRD-Y in Tet-TauRD-Y cells, but did not result in a significant stabilization after doxycycline addition (Supplementary Fig. 4j). In contrast, aggregate-containing Tet-TauRD-Y* cells treated with VCP siRNA accumulated significantly higher amounts of TauRD-Y both in the absence or presence of doxycycline, indicating an aggregate-specific role of VCP (Supplementary Fig. 4j).

Importantly, VCP also co-localized with aggregates of full-length Tau (FLTau-Y) in FLTau-Y* cells (Supplementary Fig. 4k), and VCP or proteasome inhibition prevented the clearance of FLTau-Y aggregates (Supplementary Fig. 4l,m), recapitulating the behavior of TauRD. To exclude a possible role of the YFP tag on Tau in VCP-mediated disaggregation, we generated HEK293T cells stably expressing non-tagged full-length Tau (FLTau) and myc-tagged Tau repeat domain (TauRD) under a Tet-regulated promoter (Tet-FLTau, Tet-FLTau* and Tet-TauRD, Tet-TauRD* cells). Similar to FLTau-Y aggregates in FLTau-Y* cells, FLTau aggregates in Tet-FLTau* cells were phosphorylated at serine 202 and threonine 205 and colocalized with VCP (Fig. 2e, Supplementary Fig. 4n). FLTau and TauRD aggregates were

resolved in a VCP and proteasome-dependent manner when Tau synthesis was halted by adding doxycycline (Fig. 2f, Supplementary Fig. 4o).

We next tested whether VCP also modulates Tau aggregation in neurons. Mouse primary neurons were transduced to express soluble TauRD-Y (Fig. 3a,b). Upon seeding with TauRD aggregates³⁷, we observed the formation of multiple inclusions of intracellular TauRD-Y (Fig. 3b). Cryo-electron tomography of TauRD-Y inclusions in aggregate-containing neurons revealed fibrillar aggregates similar to the aggregates in TauRD-Y* cells (Fig. 3c). The lower cytosolic density of neurons allowed the observation that the TauRD-Y fibrils were coated with globular domains consistent with the presence of YFP on TauRD (Supplementary Fig. 4p), as previously observed for other amyloidogenic proteins fused to fluorescent protein^{53,54}. Aggregate seeding in neurons was accompanied by a ~40% decrease in cell viability (Fig. 3d). Most of the neuronal TauRD-Y inclusions stained positive for VCP (Fig. 3b). Treatment with the VCP inhibitor NMS-873 for 4 h caused a massive accumulation of TauRD aggregates in seeded neurons, in some cases occupying most of the cell body area (Fig. 3e). No inclusions were observed in unseeded cells upon VCP inhibition (Fig. 3e). These results demonstrate that VCP functions in TauRD-Y disaggregation in neurons.

Disaggregation depends on substrate ubiquitylation

Ubiquitylation of VCP substrates, particularly the formation of lysine 48 (K48) linked polyubiquitin chains, is required for VCP recruitment^{18,19,30,50}. We therefore analyzed immunoprecipitates of TauRD-Y for the presence of ubiquitin. Only in TauRD-Y* cells containing aggregated TauRD-Y was the protein detectably modified by the addition of 1 to 4 ubiquitin molecules (Fig. 4a). Analysis with a K48-specific antibody verified the presence of

K48-linked ubiquitin (Fig. 4a). Immunofluorescence imaging also showed that the TauRD-Y aggregates stained positive for K48-linked ubiquitin chains (Fig. 4b, Supplementary Fig. 5a), while K63-linked ubiquitin was not detectable (Supplementary Fig. 5a). Likewise, the TauRD-Y inclusions in primary neurons colocalized with poly-ubiquitin chains (Supplementary Fig. 5b). K48-linked ubiquitin signal was also observed on the aggregates of untagged FLTau and TauRD (Supplementary Fig. 5c).

Inhibition of the ubiquitin-activating enzyme E1 with the specific inhibitor MLN7243⁵⁵ efficiently blocked ubiquitin conjugation (Supplementary Fig. 6a). TauRD-Y inclusions were still present but were no longer ubiquitin K48-reactive (Fig. 4b, Supplementary Fig. 6b). VCP was not recruited to these aggregates (Fig. 4c, Supplementary Fig. 6c), and both disaggregation and degradation of TauRD-Y in Tet-TauRD-Y* cells were blocked (Fig. 4d, Supplementary Fig. 6d). MLN7243 treatment also prevented the degradation of soluble TauRD-Y to a degree similar to proteasome inhibition (Supplementary Fig. 6e). Together these data show that VCP recruitment requires ubiquitylation of aggregated Tau, followed by disaggregation and remodeling to species that are accessible for proteasomal degradation.

Functions of VCP and Hsp70 in disaggregation

Disaggregation of both heat stress-induced and amyloid-like aggregates in mammalian cells has been assigned to the Hsp70 chaperone system^{11-13,16}. Our findings raised the possibility of a functional cooperation between VCP and Hsp70 in these processes. To determine whether VCP participates in dissolving heat-induced aggregates, we expressed the metastable protein firefly luciferase (Fluc) fused to GFP in HEK293 cells. Heat stress at 43 °C for 2 h combined with proteasome inhibition resulted in the formation of large (~2-3 µm) Fluc-GFP inclusions⁵⁶

(Supplementary Fig. 7a). Unlike the TauRD-Y inclusions, the Fluc-GFP aggregates did not stain with an amyloid-specific dye (Supplementary Fig. 7a), suggesting that they were amorphous in structure. The Fluc-GFP aggregates were ubiquitin-negative and did not co-localize with VCP (Supplementary Fig. 7b-c). Accordingly, VCP inhibition with NMS-873 did not interfere with disaggregation (Supplementary Fig. 7d), arguing against a role of VCP in this process. However, inhibition of the ATPase activity of Hsp70 with the inhibitor VER-155008⁵⁷ prevented Fluc-GFP disaggregation (Supplementary Fig. 7d), confirming the role of the Hsp70 system in disaggregation.

To investigate whether Hsp70 participates in TauRD-Y disaggregation, we treated Tet-TauRD-Y* cells with VER-155008 or with NMS-873 and stopped TauRD-Y synthesis with doxycycline. VCP inhibition stabilized both large ($>1.5 \mu\text{m}^2$) and small ($<1.5 \mu\text{m}^2$) TauRD-Y inclusions (Supplementary Fig. 8a-b). In contrast, Hsp70 inhibition stabilized large aggregates only partially and resulted in a marked accumulation of small inclusions, consistent with VCP acting before Hsp70 in the disaggregation process (Supplementary Fig. 8a-b). These findings suggested that Hsp70 cooperates with VCP in disaggregation, either by dissociating fragments generated by VCP and/or by preventing re-aggregation of TauRD liberated from inclusions by VCP. Since Hsp70 was not enriched on TauRD-Y aggregates in the proteomic analysis (Supplementary Table 1), its interaction with TauRD may be transient.

Effects of VCP mutants on Tau disaggregation

Point mutations in VCP are associated with dominantly inherited disorders such as Inclusion body myopathy with Paget disease of bone and frontotemporal dementia (IBMPFD)²⁶ and vacuolar tauopathy²⁰. These mutations lead to a dominant negative loss or alteration of VCP

function, presumably due to the oligomeric nature of VCP^{58,59}. The mutation D395G (DG), associated with vacuolar tauopathy is located in the D1 ATPase domain of VCP (Fig. 5a). It has been reported to have a mildly reduced capacity to disaggregate Tau fibrils in an in vitro system, due to a ~30% reduced ATPase activity²⁰. The IBMPFD mutations, A232E (AE) and R155H (RH), are located in the D1 ATPase domain and in the N-domain, respectively, and are associated with enhanced ATPase activity compared to wild type (WT) VCP³¹ (Fig. 5a). We tested whether these mutations impair Tau disaggregation in our cellular model using the ATPase defective VCP double-mutant E305Q/E578Q (EQ/EQ)⁶⁰ (Fig. 5a) as a control. The mutant proteins, carrying a C-terminal myc-tag, were transiently overexpressed in Tet-TauRD-Y* cells for 24 h and then TauRD-Y synthesis was stopped with doxycycline to observe disaggregation. Note that mutant VCP was expressed in cells containing pre-formed aggregates to exclude a potential role of VCP in aggregate seeding⁶¹. The myc-tagged mutant proteins were present in hexamers that migrated on native PAGE like WT VCP (Supplementary Fig. 9a) and colocalized with TauRD-Y aggregates (Fig. 5b).

As expected, expression of the ATPase defective VCP (EQ/EQ) effectively prevented TauRD-Y aggregate clearance, even though the expression levels of this mutant were relatively low when compared with the other constructs (Fig. 5c,d). Moreover, the TauRD-Y aggregates increased in size upon VCP (EQ/EQ) expression as observed previously for inhibition of VCP activity by NMS-873 (Supplementary Fig. 4g), presumably reflecting a shift of soluble TauRD to the aggregates (Supplementary Fig. 2a). However, none of the disease-related VCP mutants, including the vacuolar tauopathy mutant DG, when expressed at the indicated levels, detectably stabilized TauRD-Y aggregates (Fig. 5b-d). Similar results were obtained when the presence of aggregates was specifically analyzed in cells expressing the mutant VCP proteins by

immunofluorescence (Supplementary Fig. 9b). In conclusion, the effect of the VCP disease mutations on disaggregation, if any, is only mild, suggesting that inhibition of aggregate clearance may not be the primary mechanism by which these mutations cause disease.

VCP generates Tau species capable of seeding aggregation

Progression of tauopathies and other neurodegenerative diseases is thought to be mediated by aggregate spreading across brain regions through a prion-like seeding mechanism^{5,6}. We speculated that the disaggregation activity of VCP could modulate the levels of aggregate species that are able to induce the aggregation of soluble Tau in recipient cells. To address this possibility, we measured the presence of seeding-competent TauRD species by FRET in cells expressing TauRD-mTurquoise2 and TauRD-Y (TauRD-TY cells)⁶² (Fig. 6a). Addition of aggregate-containing total lysates from control TauRD-Y* cells induced TauRD aggregation in reporter cells (Supplementary Fig. 10a-b). Strikingly, treatment of TauRD-Y* cells with the VCP inhibitor NMS-873 reduced the seeding capacity of lysates by more than 50%, when equivalent amounts of TauRD-Y were compared (Fig. 6b). In contrast, such a reduction in seeding was not observed when cells were treated with proteasome inhibitor (Epoxomicin) or Hsp70 inhibitor (VER-155008) (Fig. 6b). However, treatment with the E1 enzyme inhibitor MLN7243, which prevented VCP recruitment to the aggregates (Fig. 4c), also caused a ~50% reduction of FRET positive TauRD-TY reporter cells. Similar effects were observed when lysates from TauRD-Y* cells transiently expressing VCP EQ/EQ were used. In contrast, expression of VCP DG did not reduce seeding (Fig. 6c, Supplementary Fig. 10c). Thus, VCP-mediated disaggregation generates seeding-active TauRD-Y species.

To characterize the seeding competent material in the presence and absence of VCP function, we fractionated lysates from TauRD-Y* cells by size-exclusion chromatography. Inclusions >0.2 μ m were removed by filtration. The majority of the remaining TauRD-Y (~70%) fractionated at a high molecular weight (HMW) of $\geq$ 40 MDa in the void volume of the column. The remainder fractionated at a low molecular weight (LMW), equivalent to the position of soluble TauRD-Y from TauRD-Y cells (Fig. 6d). Both fractions isolated from TauRD-Y* cells were seeding competent, but the specific seeding activity of HMW TauRD-Y (% FRET positive cells per ng TauRD-Y) was ~10-fold higher than that of the LMW fraction (Supplementary Fig. 10d). Treatment with VCP inhibitor NMS-873 strongly reduced the total amount of TauRD-Y species <0.2 μ m, consistent with the reduced seeding activity after VCP inhibition. Moreover, the ratio between HMW and LMW peaks was reversed as the former was decreased by ~80% and the latter by only ~25% (Fig. 6d). However, the specific seeding activity of TauRD in both fractions remained unchanged (Supplementary Fig. 10d), suggesting that VCP inhibition reduces the amount of seeds but not their intrinsic seeding potency. Together these results demonstrate that the disaggregation activity of VCP increases the available pool of seeding competent TauRD species.

Discussion

Metazoa do not possess a homologue of the AAA+ ATPase Hsp104 responsible for protein disaggregation in bacteria, fungi and plants^{10,63}. Instead, dissociation of large protein aggregates, including amyloid fibrils, in animal cells is generally ascribed to the Hsp70/Hsp110/Hsp40 chaperone system^{10,12-14,16}. Here we provide evidence that the AAA+ ATPase VCP functions in disaggregating amyloid fibrils of Tau in human cells and primary mouse neurons (Fig. 7). VCP

is distinct from Hsp104 in that it requires the target aggregate to be ubiquitylated, a critical element of control to ensure specificity and avoid dissolution of functional protein assemblies⁶⁴. Consistent with such a control function, ubiquitylation likely occurs after aggregate formation as an essential prerequisite for disaggregation (Fig. 7). The E3 ubiquitin ligases involved in this process remain to be identified. Moreover, aggregate ubiquitylation ensures that disaggregation by VCP is coupled to degradation by the 26S proteasome. Additionally, the proteasomal 19S ATPase may contribute to disaggregation, consistent with its ability to fragment fibrils in vitro⁶⁵. The Hsp70 chaperone system is required for the overall efficiency of the reaction, either by further dissociating aggregate fragments produced by VCP action or by preventing re-aggregation of Tau molecules that have been liberated from the fibrils (Fig. 7). As the smaller TauRD aggregates that accumulated upon Hsp70 inhibition were no longer VCP positive, disaggregation by VCP may allow Hsp70 to access aggregates of non-ubiquitylated Tau. This possibility is consistent with the reported ability of the Hsp70 system to disaggregate Tau aggregates in vitro¹⁵.

Support for the physiological relevance of VCP in antagonizing amyloid aggregation is provided by mutations in VCP that are associated with the deposition of ubiquitylated aggregates in neurodegenerative diseases such as vacuolar tauopathy and IBMPFD^{20,28,58}. However, the vacuolar tauopathy-associated VCP mutation D395G²⁰ and the IBMPFD mutations A232E and R155H²⁶ did not detectably impair VCP-mediated Tau disaggregation in our cellular model. Although even a small inhibitory effect on disaggregation may contribute to aggregate pathology in neurons over decades, the disease mutations may alternatively affect other steps during aggregate formation, including aggregate seeding and Tau degradation in cooperation with the proteasome. Indeed, an increase in intracellular aggregation is observed when VCP is inhibited

in recipient cells at the time of seeding⁶¹ or when VCP D395G is expressed in the recipient cells²⁰. Note that we introduced the mutant VCP proteins in cells containing preexistent Tau aggregates to exclude a potential role of VCP in the process of aggregate seeding.

Our finding that clearance of Tau aggregates by VCP generates smaller seeding competent species as a byproduct (Fig. 7) provides a plausible explanation for how VCP can exert both neuroprotective and neurotoxic effects. Indeed, overexpression of a VCP homologue in a *Drosophila* model of polyglutamine protein aggregation hastened the degenerative phenotype⁶⁶. Transcellular aggregate spreading has been recognized as a major driver of neurodegenerative disease progression^{5,6,67}, and generation of seeding competent species may be an inevitable consequence of amyloid clearance mechanisms via disaggregation, not only by VCP but also by the Hsp70 system¹⁵. We note, however, that in contrast to inhibition of VCP, neither Hsp70 nor proteasome inhibition had a significant effect on the generation of seeding competent Tau species in our model, suggesting that their function is not directly coupled to seed production.

VCP-mediated aggregate disassembly followed by proteasomal degradation provides an important alternative to autophagy as a mechanism for the elimination of terminally aggregated proteins. Based on our results, both activation and inhibition of this pathway may have beneficial effects dependent on the specific disease context. Non-human AAA+ ATPases with augmented disaggregase activity are currently being developed with the aim to reverse pathogenic protein aggregation^{68,69}. Boosting cellular aggregate clearance, perhaps in combination with proteasome activation⁷⁰, may offer a potential therapeutic strategy as long as the production of seeding competent species can be controlled.

Main Figures

Fig. 1 TauRD-Y forms amyloid-like aggregates that are cleared from cells. **a** Schematic representation of Tau constructs used in this study. TauRD-Y, the repeat domain, and FLTau-Y, the 0N4R Tau isoform of full-length (FL) Tau with two frontotemporal dementia-associated

366 mutations, P301L and V337M, fused to YFP via 21 amino acid (aa) linkers. **b** Schematic
 367 representation of aggregate seeding. Extracellular addition of preformed Tau aggregates induces
 368 templating of intracellular Tau into aggregates that propagate with cell division. Aggregate seeds
 369 may be generated in vitro or be contained in cell lysate. TauRD-Y, naïve cells containing soluble
 370 TauRD-Y; TauRD-Y*, cells containing TauRD-Y aggregates. **c** Staining of TauRD-Y and
 371 TauRD-Y* cells with the amyloid-specific dye Amylo-Glo (magenta). White dashed lines
 372 indicate cell boundaries. Scale bar, 10 μ m. **d** TauRD-Y aggregates are fibrillar in structure. Left,
 373 a 1.7 nm thick tomographic slice of a TauRD inclusion from TauRD-Y* cells is shown. Red,
 374 blue and green arrowheads indicate representative TauRD-Y fibril, microtubule and actin,
 375 respectively. Right, 3D rendering of corresponding tomogram showing TauRD-Y fibrils (red),
 376 Golgi (purple), mitochondria (yellow) and ER (green). Scale bars, 200 nm, inset 40nm.
 377 **e** Aggregate clearance. Left, TauRD-Y* cells treated for 24 h with cycloheximide (CHX; 50
 378 μ g/mL) where indicated. Nuclei were counterstained with DAPI (blue). Scale bar, 10 μ m. Right,
 379 quantification of TauRD-Y foci. Mean $\pm$ s.d.; n=3; 500-600 cells analyzed per experiment;
 380 *p<0.05 (p=0.0151) from two-tailed Student's paired t-test. **f** Left, representative images of Tet-
 381 TauRD-Y* cells treated with Dox for the indicated times. Right, quantification of inclusions per
 382 cell and average inclusion size (μ m²). Mean $\pm$ s.d.; n=3. Scale bar, 10 μ m.

Fig. 2 Disaggregation of Tau aggregates is dependent on VCP activity. **a** Volcano plot of TauRD-Y interactome from TauRD-Y and TauRD-Y* cells. Unlabeled green and blue symbols represent proteasome subunits of 19S and 20S, respectively. VCP and its cofactors are highlighted. **b** Association of VCP with TauRD-Y inclusions. Immunofluorescence staining of VCP (red) and YFP fluorescence of TauRD-Y (green) in TauRD-Y and TauRD-Y* cells. Scale bar, 10 μ m. **c** Filter trap analysis of lysates from Tet-TauRD-Y* cells treated for 24 h with doxycycline (Dox; 50 ng/mL) alone or in combination with NMS-873 (NMS; 2.5 μ M) or Epoxomicin (Epox; 50 nM). Aggregated and total TauRD-Y levels were determined by immunoblotting against GFP. GAPDH served as loading control. **d** Representative images of Tet-TauRD-Y* cells treated as in (c). Scale bar, 10 μ m. **e** Association of VCP with FLTau inclusions. Immunofluorescence staining of VCP (red) and Tau with Tau-5 antibody (green) in FLTau and FLTau* cells. Scale bar, 10 μ m. **f** Filter trap analysis of lysates from Tet-FLTau* cells treated for 24 h with doxycycline (Dox; 50 ng/mL) alone or in combination with NMS-873 (NMS; 2.5 μ M) or Epoxomicin (Epox; 50 nM). Aggregated and total FLTau levels were determined by immunoblotting using AT8 and Tau-5 antibodies, respectively. GAPDH served as loading control.

401
402

Fig. 3 Disaggregation of TauRD-Y aggregates in primary neurons is dependent on VCP activity. **a** Schematic representation of experimental timeline in primary neurons. DIV, days in vitro. **b** Association of VCP with TauRD-Y inclusions in primary neurons. Immunofluorescence staining of VCP (red) and YFP fluorescence of TauRD-Y (green). Arrows point to TauRD-Y inclusions containing VCP. Scale bars, 10 μ m. **c** Fibrillar TauRD-Y aggregates in primary neurons. Left, a 1.4 nm thick tomographic slice of a TauRD inclusion from neurons is shown.

Red arrows indicate TauRD-Y fibrils. Right, 3D rendering of corresponding tomogram showing TauRD-Y fibrils (red), vesicles (blue) and ER (green). Scale bar, 350 nm. **d** Toxicity of TauRD-Y aggregation in primary neurons. Untransduced neurons or neurons transduced with TauRD-Y were treated with cell lysates containing TauRD-Y aggregates for 4 days where indicated. Viability was measured using an MTT assay. Mean $\pm$ s.d.; n=3; *p<0.05 (Control + Seed vs TauRD-Y + Seed, p=0.0184; TauRD-Y - Seed vs TauRD-Y + Seed, p=0.142); n.s. non-significant (Control - Seed vs Control + Seed, p=0.2074) from two-way ANOVA with Tukey post hoc test. **e** Left, representative images of primary neurons expressing TauRD-Y, exposed to cell lysates containing TauRD-Y aggregates and treated for 4 h with NMS-873 (NMS; 0.5 μ M) where indicated. Scale bars, 20 μ m. Right, quantification of area occupied by TauRD-Y aggregates as a percentage of total area of cells. Mean $\pm$ s.d.; n=3; **p<0.01 (+ Seed + DMSO vs + Seed + NMS, p=0.0098); n.s. non-significant (- Seed + DMSO vs - Seed + NMS, p=0.2998) from unpaired t test.

Fig. 4 Ubiquitination is necessary for VCP recruitment and disaggregation.

a Immunoprecipitation of TauRD-Y from lysates of control HEK cells, TauRD-Y and TauRD-Y* cells in the presence of 0.1% SDS using anti-GFP beads. Eluates were analyzed by immunoblotting with antibodies against GFP and K48-linked ubiquitin chains (UbK48). The TauRD-Y band shows the unmodified protein and arrowheads point at increments in ubiquitin conjugation (Ub₁-Ub₄). **b** Inhibition of ubiquitylation of TauRD inclusions. TauRD-Y* cells were treated for 12 h with MLN7243 (MLN; 0.5 μ M) followed by immunofluorescence analysis with a UbK48 antibody (red). **c** Inhibition of TauRD ubiquitylation prevents VCP association. TauRD-Y* cells were treated as in (b). VCP (red) was visualized by immunofluorescence. Scale bars: 10 μ m. **d** Filter trap analysis of lysates from Tet-TauRD-Y* cells treated for 24 h with 50

435 ng/mL doxycycline alone or in combination with 0.2 μ M MLN7243 or 50 nM Epoxomicin.

436 Aggregated and total TauRD-Y levels were determined by immunoblotting against GFP.

437 GAPDH served as loading control.

438

Fig. 5 Effects of VCP mutants on Tau disaggregation. **a** Schematic representation of VCP variants used in this study. Wild type (WT), D395G (DG), A232E (AE), R155H (RH) and E305Q/E578Q (EQ/EQ) VCP were tagged with a C-terminal myc-tag. Red asterisks indicate relative positions of the mutations. **b** Association of transiently expressed VCP variants with TauRD-Y inclusions. Immunofluorescence staining of myc (red) and YFP fluorescence of TauRD-Y (green) in TauRD-Y* cells. Scale bar, 10 μ m. **c** Filter trap analysis of lysates from

445 Tet-TauRD-Y* cells transiently transfected with empty vector (EV) or indicated VCP variants
446 for 24 h, and treated for another 24 h with doxycycline (Dox; 50 ng/mL). Aggregated TauRD-Y
447 and overexpressed VCP levels were determined by immunoblotting against GFP and myc,
448 respectively. GAPDH served as loading control. **d** Left, representative images of Tet-TauRD-Y*
449 cells treated as in (c). Scale bar, 10 μ m. Right, quantification of aggregate foci in (d). Mean $\pm$
450 s.d.; n=3; > 400 cells analyzed per experiment; *p<0.05 (EV + Dox vs EQ/EQ + Dox, p=
451 0.0209); n.s. non-significant (EV + Dox vs WT + Dox, p= 0.5017; EV + Dox vs DG + Dox, p=
452 0.7172) from two-tailed Student's paired t-test.

Fig. 6 VCP-mediated disaggregation generates seeding-competent TauRD-Y species.

a Experimental scheme to assess the effects of inhibitors of VCP, Hsp70, proteasome and ubiquitylation on the level of TauRD-Y aggregate seeds in TauRD-Y* cells. **b** Flow cytometry analysis of aggregate seeding in TauRD-TY reporter cells after addition of lysates from TauRD-Y* cells treated with NMS (VCP inhibitor), VER (Hsp70 inhibitor), Epox (proteasome inhibitor) and MLN (ubiquitylation inhibitor). Fold changes with respect to DMSO treated cells are shown. Mean $\pm$ s.d.; NMS and Epox $n=4$, VER $n=5$, MLN $n=3$; *** $p<0.001$ (DMSO vs NMS, $p=8.69 \times 10^{-7}$; DMSO vs MLN, $p=4.2 \times 10^{-5}$) from one-way ANOVA with Tukey post hoc test. **c** Flow cytometry analysis of aggregate seeding in TauRD-TY reporter cells after addition of lysates from TauRD-Y* cells transfected with empty vector (EV), wild-type (WT), D395G (DG) and

463 ATPase deficient E305Q/E578Q (EQ/EQ) VCP constructs. Fold changes with respect to EV
464 transfected cells are shown. Mean $\pm$ s.d. n=3; ***p<0.001 (EV vs EQ/EQ, p= 0.0007) from one-
465 way ANOVA with Tukey post hoc test. **d** Left, fractionation of TauRD-Y from DMSO and
466 NMS-873 treated lysates of TauRD-Y* cells by size exclusion chromatography (SEC). Equal
467 amounts of total lysate protein were analyzed. Y-axis represents the relative amount of TauRD-Y
468 in the high molecular weight (HMW) and the low molecular weight (LMW) fractions quantified
469 by immunoblotting. Right, ratio of TauRD-Y in HMW/LMW fractions. Mean $\pm$ s.d.; n=3.
470 **p<0.01 (p= 0.002) from two-tailed Student's paired t-test.

Fig. 7 Model of VCP-mediated disaggregation of amyloid-like Tau aggregates. Modification of aggregates with K48-linked ubiquitin chains allows recruitment of VCP. VCP may extract ubiquitylated Tau monomer from fibril ends or from within fibrils. Monomers are directly targeted for proteasomal degradation. Extraction from internal sites results in fibril fragmentation and generation of oligomers that act as seeds for aggregation. Completion of oligomer disaggregation may be accomplished by the 19S proteasome, perhaps with participation of the Hsp70 system (purple). Hsp70 may also contribute to aggregate clearance by preventing re-aggregation of disaggregation products.

Methods

Plasmids

The N1-TauRD (P301L/V337M)-EYFP and N1-FLTau (0N4R, P301L/V337M)-EYFP constructs were previously described^{37,62}. To generate TauRD (P301L/V337M) and FLTau (0N4R, P301L/V337M) without fluorescent tag, a stop codon was introduced in the N1-TauRD (P301L/V337M)-EYFP and N1-FLTau (0N4R, P301L/V337M)-EYFP plasmids after the Tau sequence using the Q5 site directed mutagenesis (SDM) kit (New England Biolabs). Tau fragments were subcloned into pcDNA3.1 by restriction digestion and further into pCW57.1-MAT2A all-in-one tet-off lentiviral backbone (a gift from David Sabatini (Addgene plasmid #100521))⁷¹ by Gibson assembly. TauRD (P301L/V337M) construct contains a C-terminal myc-tag separated from TauRD by a 4 aa (GGSG) linker.

Wild type (WT) VCP (Addgene #23971), A232E VCP (Addgene #23973), R155H VCP (Addgene #23972) and E305Q/E578Q VCP (Addgene #23974) sequences were derived from plasmids described previously³⁴. A C-terminal myc tag and stop codon was introduced using SDM followed by subcloning the VCP-myc fragments into pcDNA3.1. The D395G VCP construct was generated by introducing the D395G mutation in WT-VCP plasmid by SDM. All mutations were verified by sequencing. The plasmid expressing wild type firefly luciferase fused to EGFP (Fluc-GFP) was previously described⁵⁶.

Lentiviral packaging plasmid pVsVg was a gift from Dieter Edbauer. psPAX2 (Addgene #12260) and pMD2.G (Addgene #12259) also used for lentiviral production were gifts from Didier Trono. pFhSynW2 TauRD (P301L/V337M)-EYFP used for TauRD-EYFP expression in mouse primary neurons was previously described⁶².

Cell lines and cell culture

Cells expressing constitutive and tet-regulated TauRD-Y (TauRD-Y and Tet-TauRD-Y cell lines, respectively), FRET biosensor TauRD-TY, and FLTau-Y cells were previously described^{37,62}. Tet-FLTau and Tet-TauRD cell lines were generated by transducing HEK293T cells with 200 µL concentrated lentivirus in presence of 0.8 µg/mL Polybrene (Sigma). Transduced cells were selected with 10 µg/mL Blasticidin (Thermo) and thereafter sorted in 96 well-plates with a BD FACS Aria III (BD Biosciences) (Imaging Facility, MPI Biochemistry). Monoclonal cell lines stably expressing FLTau and TauRD were screened by immunofluorescence staining and immunoblotting followed by amplification.

All cell lines were cultured in Dulbecco's Modified Eagle Medium (Biochrom) supplemented with 10% FBS (Gibco), 2 mM L-glutamine (Gibco), 100 units/mL penicillin and 100 µg/mL streptomycin (Gibco), and non-essential amino acid cocktail (NEAA) (Gibco) and grown at 37 °C at 5% CO₂. TauRD-TY and FLTau-Y cells were maintained in presence of 200 µg/mL G418 (Gibco). HEK293 cells stably expressing Fluc-GFP were maintained in presence of 50 µg/mL hygromycin (Thermo).

Generation of cell lines propagating Tau aggregates

Tau aggregation was induced by addition of TauRD aggregates as described previously³⁷. Briefly, HEK293 cells expressing TauRD-Y were initially treated with fibrillar aggregates generated in vitro from purified TauRD and clones that displayed the ability to maintain TauRD-Y aggregates for multiple passages were selected. Aggregate-containing TauRD-Y* cells were lysed in Triton buffer (0.05% Triton X-100/PBS (Gibco) supplemented with protease inhibitor cocktail (Roche, EDTA-free) and benzonase (prepared in-house)) and kept on ice for 20 min.

Cell lysate was centrifuged at 1,000 x g for 5 min and the supernatant was collected. Protein concentration in cell lysates was determined using Bradford assay (Bio-Rad). 30 µg of freshly prepared lysate was diluted in 100 µL Opti-MEM Reduced Serum Medium (Gibco). In a separate tube 4 µL Lipofectamine 2000 was diluted in 100 µL Opti-MEM and incubated at room temperature (RT) for 5 min. Contents of the tubes were gently mixed and incubated at RT for 20 min. The lysate-lipofectamine mixture was applied to naïve cells expressing soluble TauRD-Y, plated at 150,000 cells/well in a 12-well plate. 24 h later, cells were transferred to a 6-well plate and 3 days later to 10 cm dishes (<200 cells per dish) for 8 days, until clearly visible colonies were observed. Colonies were screened for the presence of YFP positive aggregates with an Axio Observer fluorescent microscope (Zeiss). Monoclonal cells displaying aggregate morphology similar to parental cells were amplified and frozen until use. TauRD, FLTau and FLTau-Y expressing cells were similarly seeded with cellular TauRD aggregates³⁷ and cultured for several days before experiments were performed with a polyclonal cell population.

Lentivirus production

For primary neuron transduction: HEK293T cells (LentiX 293T cell line, Takara) for lentiviral packaging were expanded to 70-85% confluency in DMEM Glutamax (+4.5 g/L D-glucose, - pyruvate) supplemented with 10% FBS (Sigma), 1% G418 (Gibco), 1% NEAA (Thermo Fisher) and 1% HEPES (Biomol). Only low passage cells were used. For lentiviral production, a three-layered 525 cm² flask (Falcon) was seeded and cells were henceforth cultured in medium without G418. On the following day, cells were transfected with the expression plasmid pFhSynW2 (TauRD-Y), the packaging plasmid psPAX2 and the envelope plasmid pVsVg using TransIT-Lenti transfection reagent (Mirus). The transfection mix was incubated for 20 min at RT. The

cell medium was exchanged in the meantime. 10 mL of transfection mix was added to the flask, followed by incubation overnight. The medium was exchanged on the following day. After 48-52 h, culture medium containing the viral particles was collected and centrifuged for 10 min at 1,200 x g. The supernatant was filtered through 0.45 µm pore size filters using 50 mL syringes, and Lenti-X concentrator (Takara) was added. After an overnight incubation at 4 °C, samples were centrifuged at 1,500 x g for 45 min at 4 °C, the supernatant was removed and the lentivirus pellet was resuspended in 150 µL TBS-5 buffer (50 mM Tris-HCl pH 7.8, 130 mM NaCl, 10 mM KCl, 5 mM MgCl₂). After aliquoting, lentivirus was stored at -80 °C.

For HEK293T transduction: HEK293T cells (LentiX 293T cell line, Takara) were transfected in 10 cm dishes with packaging plasmid psPAX2, envelope plasmid pMD2.G and expression plasmids (pCW Tet-off FLTau and TauRD) using Lipofectamine 3000. 48 h later virus-containing media was harvested and centrifuged for 5 min at 1,000 x g. Lenti-X concentrator was added to supernatant, incubated overnight at 4 °C and the following day centrifuged for 45 min at 1,500 x g at 4 °C. The lentiviral pellet was resuspended in 1 mL PBS, aliquoted and stored at -80 °C.

Primary neuronal cultures

Primary cortical neurons were prepared from E15.5 CD-1 wild type mouse embryos. All experiments involving mice were performed in accordance with the relevant guidelines and regulations. Pregnant female mice were sacrificed by cervical dislocation. The uterus was removed from the abdominal cavity and placed into a 10 cm sterile Petri dish on ice containing dissection medium, consisting of Hanks' balanced salt solution (HBSS) supplemented with 0.01 M HEPES, 0.01 M MgSO₄ and 1% penicillin/streptomycin. Each embryo was isolated,

heads were quickly cut, and brains were removed from the skull and immersed in ice-cold dissection medium. Cortical hemispheres were dissected, and meninges were removed. The cortices were collected in a 15 mL sterile tube and digested with 0.25% trypsin containing 1 mM ethylenediaminetetraacetic acid (EDTA) and 15 μ L 0.1% DNase I for 20 min at 37 °C. The digestion was stopped by removing the supernatant and washing the tissue twice with Neurobasal medium (Invitrogen) containing 5% FBS. The tissue was resuspended in 2 mL Neurobasal medium and triturated to achieve a single cell suspension. Cells were spun at 130 x g, the supernatant was removed, and the cell pellet was resuspended in Neurobasal medium with 2% B-27 supplement (Invitrogen), 1% L-glutamine (Invitrogen) and 1% penicillin/streptomycin (Invitrogen). For immunofluorescence microscopy, neurons were cultured in 24-well plates on 13 mm coverslips coated with 1 mg/mL poly-D-lysine (Sigma) and 1 μ g/mL laminin (Thermo Fisher Scientific) (100,000 neurons per well). For biochemical assays, neurons were cultured in 12-well plates coated in the same way (200,000 neurons per well). For viability measurements, neurons were cultured in 96-well plates coated in the same way (18,000 neurons per well). Lentiviral transduction was performed at 10 days in vitro (DIV 10). Virus preparation was thawed and immediately added to freshly prepared neuronal culture medium. Neurons in 24-well plates received 1 μ L of virus per well. Neurons in 12-well plates received 1.5 μ L of virus per well. Neurons in 96-well plates received 0.15 μ L of virus per well. A fifth of the medium from cultured neurons was removed and the equivalent volume of virus-containing medium was added. Three days after transduction (DIV 13), 2, 6 or 12 μ g of HEK293 cell lysate containing TauRD-Y aggregates, mixed with fresh medium (one tenth of medium volume in the well), were added to the neuronal cultures in 96, 24 or 12-well plates, respectively. HEK293 cell lysate for

neurons was prepared by brief sonication of aggregate-containing cells in PBS. Six days after transduction (DIV 16), neurons were treated with inhibitor or DMSO as control.

Neuronal viability assay

Viability of transduced neurons was determined using Thiazolyl Blue Tetrazolium Bromide (MTT; Sigma-Aldrich). Seven days after transduction (DIV 17), cell medium was exchanged for 100 μ L of fresh medium, followed by addition of 20 μ L of 5 mg/ml MTT/PBS and incubation for 4 h at 37 °C, 5% CO₂. Subsequently, 100 μ L solubilizer solution (10% SDS, 45% dimethylformamide in water, pH 4.5) was added, and on the following day absorbance was measured at 570 nm. Each condition was measured in triplicates per experiment and absorbance values were averaged for each experiment. The individual values for the ‘Control-Seed’ condition obtained for each of the three experiments were normalized by the mean of these values. The values of all other conditions were normalized by the new value of the ‘Control-Seed’ condition of the corresponding independent experiment.

Plasmid and siRNA transfection

Plasmids were transfected with Lipofectamine 2000 (Thermo) after manufacturer’s instructions in 12- or 6-well plates using 2 or 4 μ g DNA. All siRNAs were obtained from Dharmacon as ON-TARGETplus SMART pools: VCP (L-008727-00-0005), Atg5 (M-004374-04-0005), Atg7 (L-020112-00-0005), PSMD11 (L-011367-01-0005), non-targeting control (D-001810-03-20). Cells were plated in 24-well plates in 500 μ L antibiotic free DMEM. 2 μ L of Dharmafect transfection reagent and 50-100 nM of siRNA were diluted each in 50 μ L Opti-MEM and incubated at RT for 5 min. Contents of the tubes were mixed gently by pipetting and incubated further at RT for 15

min. Subsequently, the transfection mixture was added to the cells drop-wise. 24 h later cells were split and plated in 12- or 6-well plates and allowed to grow for up to 96 h before immunoblotting or immunofluorescent staining.

Antibodies and chemicals

The following primary antibodies were used for immunoblotting or immunofluorescent staining: anti-VCP (AbCam #ab11433), anti-VCP (Novus Biologicals #NB100-1558) (Fig. 2e and Supplementary Fig. 9a), anti-GFP (Roche #11814460001), anti-ubiquitin Lys48-specific (Millipore #05-1307), anti-ubiquitin Lys63-specific (AbCam #ab179434), anti-ubiquitin (P4D1) (SantaCruz #sc-8017), anti-Tau (pS356) (GeneTex #GTX50165), anti-phospho-Tau (S202, T205) (Thermo #MN1020), anti-NPLOC4 (Sigma #HPA021560), anti-UFD1L (AbCam #ab96648), anti-ubiquitin FK2 (Millipore #04-263), anti-Tau (Tau-5) (Thermo #MA5-12808), anti-human Tau/Repeat Domain (2B11) (IBL #JP10237), anti-LC3B (Sigma #L7543), anti-Atg5 (Cell Signalling #2630S), anti-Atg7 (Cell Signalling #8558), anti-PSMD11 (Proteintech #14786-1-AP), anti-myc (in house, 9E10), anti-GAPDH (Millipore #MAB374), anti-Tubulin (Sigma #T6199).

The following secondary antibodies were used: Cy5-conjugated anti-mouse (Thermo #A10524), Cy-5 conjugated anti-rabbit (Thermo #A10523), Alexa Fluor 647 AffiniPure anti-mouse (Jackson ImmunoResearch #715-605-151), DyLight 488 anti-mouse (Thermo #SA5-10166), anti-mouse IgG peroxidase conjugate (Sigma #A4416) or anti-rabbit peroxidase conjugate (Sigma #A9169), IRDye 680RD anti-mouse (LI-COR #926-68070), IRDye 800CW anti-rabbit (LI-COR #926-32211).

The following chemicals were used: Cycloheximide (Sigma), doxycycline (Sigma), 3-methyladenine (Invivogen), bafilomycin A1 (Invivogen), epoxomicin (Cayman Chemical), NMS-873 (Sigma), CB-5083 (Cayman Chemical), VER-155008 (Sigma), MLN7243 (Chemietek). Solutions in DMSO were stored at -20 °C. 3-Methyladenine was dissolved in H₂O after manufacturer's instructions and applied immediately to cells.

Immunofluorescence staining

HEK293 cells were grown on poly-L-lysine (NeuVito) coated glass coverslips for 24-48 h in 12-well plates before any treatment. At the end of the experiment, media was aspirated and cells were directly fixed in 4% formaldehyde (w/v) (Thermo, Methanol-free) in PBS for 10 min at RT, washed once with PBS and permeabilized in 0.1% Triton X-100/PBS for 5 min. Samples were blocked using 5% low-fat dry milk dissolved in 0.1% Triton X-100/PBS for 1 h at RT, followed by incubation with primary antibodies in blocking solution and fluorescently labelled secondary antibodies in PBS. Nuclei were counterstained with DAPI. For amyloid staining, after fixation and permeabilization, cells were incubated with Amylo-Glo (Biosensis TR-300-AG) at a dilution of 1:200/PBS with gentle shaking followed by washing twice with PBS. Cells were not counterstained with DAPI. Coverslips were mounted in fluorescent mounting medium (Dako) on glass slides and stored at 4 °C until imaging.

Primary neurons: Primary neurons were fixed at DIV 17 with 4% paraformaldehyde (Santa Cruz) (PFA)/PBS for 15 min; remaining free aldehyde groups of PFA were blocked with 50 mM ammonium chloride/PBS for 10 min at RT. Cells were rinsed once with PBS and permeabilized with 0.25% Triton X-100/PBS for 5 min. After washing with PBS, blocking solution consisting of 2% BSA (w/v) (Roth) and 4% donkey serum (v/v) (Jackson

ImmunoResearch Laboratories) in PBS was added for 30 min at RT. Coverslips were transferred to a light protected humid chamber and incubated with primary antibodies diluted in blocking solution for 1 h. Cells were washed with PBS and incubated with secondary antibody diluted in blocking solution for 30 min and counterstained with DAPI. Coverslips were mounted using Prolong Glass fluorescence mounting medium (Invitrogen).

Image acquisition (Microscopy)

Images were acquired with a Zeiss LSM 780, Leica SP8 FALCON (Imaging Facility, MPI Biochemistry) or a Leica TCS SP8 Laser-scanning confocal microscope (Imaging Facility, MPI Neurobiology) and analyzed using FIJI/ImageJ software. For multifuorescent imaging, samples stained with individual fluorophores were used to correct emission bandwidths and exposure settings to minimize spectral crossover.

Quantification of aggregates/cell and average size

Confocal z-stacks were used to create a maximum intensity projection (MIP) using the image acquisition software ZEN (Zeiss). MIPs were further segmented to define aggregate foci by thresholding. Aggregate number and size were computed by the Analyze Particle function (Size: 0-infinity). Cell numbers were determined by counting DAPI stained nuclei with the Cell Counter plugin. Experiments were performed at least 3 times in biologically independent repeats. For neuronal aggregates, neuronal cytoplasm area was calculated by manually selecting a region of interest (ROI) around the soma of the neuron and utilizing the Analyze feature. Aggregate foci were identified by thresholding the MIP images and aggregate size (area), within the previously selected ROI, was calculated by the Analyze Particle function. The percentage of total neuron

area occupied by aggregate was the quotient of the division between aggregate area and neuronal cytoplasmic area: (Aggregate area)/(Cytoplasm area) x 100. 60 individual neurons were imaged per condition, in 3 biologically independent replicates.

mRNA quantification

Total RNA was isolated using the RNeasy Mini Kit (Qiagen) and reverse transcribed with iScript™ cDNA Synthesis Kit (Biorad) according to manufacturers' instructions. Quantitative real-time PCR was performed with PowerUp™ SYBR™ Green Master Mix (Applied Biosystems) with a StepOnePlus Real-Time PCR System (Applied Biosystems). CT values were measured and fold changes calculated by the $\Delta\Delta C(T)$ method⁷² using the RPS18 gene as reference. The following primers were used: RPS18 forward 5'-TGTGGTGTGAGGAAAGCA-3' and reverse 5'-CTTCAGTCGCTCCAGGTCTT-3'; Tau forward: 5'-AGCAACGTCCAGTCCAAGTG-3' and reverse: 5'-CCTTGCTCAGGTCAACTGGT-3'.

Correlative light and electron microscopy (CLEM), cryo-focused ion beam (FIB) and cryo-Electron Tomography

2 x 10⁴ TauRD-Y* cells or 1 x 10⁵ neurons were seeded on EM grids (R2/1, Au 200 mesh grid, Quantifoil Micro Tools) in a 35 mm dish or 24-well plate and cultured for 24 h or transduced with lentivirus and treated with aggregate-containing cell lysate as described earlier in section 'Primary neuronal cultures'. The grids were blotted for 10 s using filter paper and vitrified by plunge freezing into a liquid ethane/propane mixture with a manual plunger. CLEM, cryo-FIB and tomographic data collection were performed as described in detail before⁷³. In brief, EM

709 grids were mounted onto modified Autogrid sample carriers⁷⁴ and then transferred onto the cryo-
710 stage of a CorrSight microscope (FEI) for cryo-light microscopy. Images of the samples and
711 TauRD-Y signal were acquired with MAPS software (FEI) in transmitted light and confocal
712 mode using a 5x and 20x lens, respectively. The samples were then transferred into a dual-beam
713 (FIB/SEM) microscope (Quanta 3D FEG, FEI) using a cryo-transfer system (PP3000T,
714 Quorum). Cryo-light microscope and SEM images were correlated with MAPS software.

715 Lamellas (final thickness, 100-200 nm) were prepared using a Ga²⁺ ion beam at 30 kV in the
716 regions of the TauRD-Y fluorescence signal. In case of TauRD-Y* cells, an additional layer of
717 platinum was sputter-coated (10 mA, 5 s) on the grids to improve conductivity of the lamellas.

718 The grids were then transferred to a Titan Krios transmission electron microscope (FEI)
719 for tomographic data collection. For the whole procedure, samples were kept at a constant
720 temperature of -180 °C. Tomographic tilt series were recorded with a Gatan K2 Summit direct
721 detector in counting mode. A GIF-quantum energy filter was used with a slit width of 20 eV to
722 remove inelastically scattered electrons. Tilt series were collected from -50° to +70° with an
723 increment of 2° and total dose of 110 e⁻/Å² using SerialEM software⁷⁵ at a nominal magnification
724 of 33,000x, resulting in a pixel size of 4.21 Å for TauRD-Y* cells and at a nominal
725 magnification of 42,000x, resulting in a pixel size of 3.52 Å for the primary neurons. In case of
726 TauRD-Y* cells, a Volta phase plate was used together with a defocus of -0.5 µm for contrast
727 improvement⁷⁶.

728 For image processing of TauRD-Y* cell tomograms, frames were aligned during data
729 collection using in-house software K2align based on previous work⁷⁷ or in case of the primary
730 neuron tomograms by using the software Morioncor2 and Tomoman
731 (<https://github.com/williamnwan/TOMOMAN>). The IMOD software package⁷⁸ was used for

tomogram reconstruction. The tilt series were first aligned using fiducial-less patch tracking, and tomograms were then reconstructed by weighted back projection of the resulting aligned images.

For segmentation, tomograms were rescaled with a binning factor of four and in case of the primary neurons tomograms filtered with a deconvolution filter (https://github.com/dtegunov/tom_deconv). Tau filaments were traced with XTracing Module in Amira using a short cylinder as a template⁷⁹. The membranes were first segmented automatically with TomoSegMemTV⁸⁰ using tensor voting, and then manually optimized in Amira.

Immunoblotting

Cells were lysed in RIPA lysis and extraction buffer (Thermo) supplemented with protease inhibitor cocktail and benzonase for 30 min on ice with intermittent vortexing. Protein concentration in total cell lysates was determined using Bradford assay (Bio-Rad) and normalized in all samples before adding 2x SDS sample buffer. Samples were denatured by boiling at 95 °C for 5 min. Proteins were resolved on NuPAGE 4-12% gradient gels (Thermo) with MES or MOPS (Thermo) running buffer at 200 V for 45 min. Proteins were transferred to nitrocellulose or PVDF membranes (Roche) in tris-glycine buffer at 110 V for 1 h. Membranes were washed once in TBS-T and blocked in 5% low-fat dry milk dissolved in TBS-T for 1 h at RT. Subsequently, blots were washed 3 times with TBS-T and probed with primary and secondary antibodies. Chemiluminescence was developed using HRP substrate (Luminata Classico, Merk) and detected on a LAS 4000 (Fuji) or ImageQuant800 (Amersham) imager. AIDA image software (Elysia Raytest) was used to quantify intensity of protein bands.

Interactome analysis by mass spectrometry

SILAC labelling of cells and TauRD-Y immunoprecipitation: Interactome analyses were performed using a stable isotope labelling by amino acids in cell culture (SILAC)-based quantitative proteomics approach⁸¹. Frozen TauRD-Y and TauRD-Y* cells were thawed in arginine lysine deficient SILAC media (PAA) containing light (L) (Arg₀, Lys₀, Sigma) and heavy (H) (Arg₁₀, Lys₈, Silantes) amino acid isotopes, respectively, and supplemented with 10% dialyzed FCS (PAA), 2 mM L-glutamine (Gibco), 100 units/mL penicillin and 100 µg/mL streptomycin (Gibco), and non-essential amino acid cocktail (Gibco). A third cell line, not part of this study but included in the PRIDE entry PXD023400, was simultaneously expanded in SILAC medium supplemented with medium (M) (Arg₆, Lys₄, Silantes) amino acid isotopes, and was processed and analyzed together with TauRD-Y and TauRD-Y* samples. Cells were passaged for a minimum of two weeks to allow efficient incorporation of amino acid isotopes into the cellular proteome. Cells from a 10 cm dish were washed in PBS, lysed by gentle pipetting in 400 µL ice cold lysis buffer (1% Triton X-100/PBS supplemented with protease inhibitor cocktail and benzonase). Lysates were sonicated briefly and centrifuged at 2,000 x g for 5 min at 4 °C. 300 µL of the supernatant was removed and protein concentration was determined using Bradford assay (Bio-Rad). 50 µL anti-GFP beads (µMACS GFP Isolation kit, Miltenyi Biotech) were added to 500 µg total protein diluted in a total volume of 800 µL lysis buffer. Lysates were incubated for 1 h at 4 °C with end over end rotation at 10 rpm. µ-Columns (Miltenyi Biotech) were placed in the magnetic field of a µMACS Separator (Miltenyi Biotech) and equilibrated with 250 µL lysis buffer before lysates were applied. Columns were washed 4 times with 1 mL cold Triton buffer and 2 times with 1 mL PBS followed by elution in 70 µL preheated 1x SDS sample buffer without bromophenol blue.

MS sample processing: 20 μ L sample from each of the H, M and L eluates was mixed and processed by the filter-aided sample preparation (FASP) method as previously described⁸². Samples were loaded in a 30 kDa centrifugation device and washed 3 times with 200 μ L freshly prepared urea buffer (UB) (8 M urea, 0.1 M Tris pH 8.5). Reduction and alkylation was performed sequentially using 10 mM DTT and 50 mM iodoacetamide in UB, respectively. Samples were washed 2 times with 200 μ L 50 mM ammonium bicarbonate (NH_4HCO_3) to remove urea before an over-night trypsin treatment. Peptides were recovered in 40 μ L NH_4HCO_3 , acidified with 12 μ L of a 25% TFA solution and dried in a vacuum concentrator. The peptides were further fractionated using home-made SAX columns in 200 μ L microtips by stacking 2 punch-outs of Empore High Performance Extraction Disk (Anion-SR) material. Peptides were sequentially eluted with 6 different Britton & Robinson buffers (BURB) of decreasing pH (pH 11, 8, 6, 5, 4, 3) and acidified to 1% TFA. The last elution step was with MeOH/water (1:1)/1% formic acid. The fractionated peptides were desalted with home-made micro-columns containing C18 Empore disks and eluted with 70% ACN 1% formic acid followed by drying in a vacuum concentrator. The samples were stored at -20 °C until analysis.

LC-MS: The desalted peptides were dissolved in 5 μ L of 5% formic acid, sonicated in an ultrasonic bath, centrifuged and transferred to MS autosampler vials. Samples were analyzed on an Easy nLC-1000 nanoHPLC system (Thermo) coupled to a Q-Exactive Orbitrap mass spectrometer (Thermo). Peptides were separated on home-made spray-columns (ID 75 μ m, 20 cm long, 8 μ m tip opening, NewObjective) packed with 1.9 μ m C18 particles (Reprosil-Pur C18-AQ, Dr Maisch GmbH) using a stepwise 115 min gradient between buffer A (0.2% formic acid in water) and buffer B (0.2% formic acid in acetonitrile). Samples were loaded on the column by the nanoHPLC autosampler at a flow rate of 0.5 μ L per min. No trap column was used. The

HPLC flow rate was set to 0.25 μ L per min during analysis. MS/MS analysis was performed with standard settings using cycles of 1 high resolution (70000 FWHM setting) MS scan followed by MS/MS scans (resolution 17500 FWHM setting) of the 10 most intense ions with charge states of 2 or higher.

MS data analysis: Protein identification and SILAC based quantitation was performed using MaxQuant (version 1.5.4.1) using default settings. The human sequences of UNIPROT (version 2019-03-12) were used as database for protein identification. MaxQuant used a decoy version of the specified UNIPROT database to adjust the false discovery rates for proteins and peptides below 1%. We used normalized MaxQuant ratios for enrichment analyses to correct for uneven total protein amounts in the SILAC-labeling states. Proteins quantified in at least 2 experiments with normalized H/L ratios ≥ 2 were considered as interactors of TauRD-Y in TauRD-Y* cells. Volcano plot was generated using Perseus1.6.2.3.

Biochemical detection of aggregated Tau

Cells were lysed for 30 min on ice in lysis buffer followed by brief sonication or 1 h in RIPA buffer. Lysates were centrifuged at 2,000 or 1,000 x g for 5 min. The supernatant was carefully removed and protein concentration was normalized across all samples. Lysates were then used for solubility or filter trap assays. Lysates were centrifuged at 186,000 x g for 1 h at 4 °C. Supernatant was removed and the pellet was washed with 200 μ L PBS and centrifuged again for 30 min. Pellets were disintegrated in PBS by pipetting and boiled in 1x SDS sample buffer. Filter trap assays were performed with 200 μ g total protein diluted in 200 μ L lysis buffer. A cellulose acetate membrane (0.2 μ m pore size, GE Healthcare) was pre-equilibrated in 0.1% SDS and affixed to the filter trap apparatus (PR648 Slot Blot Blotting Manifold, Hoefer). Samples were

loaded and allowed to completely pass through the filter under vacuum. Wells were washed 3 times with 200 μ L 0.1% SDS/H₂O followed by standard immunoblotting of the membrane.

Detection of Tau ubiquitylation

Cells were lysed as described in section Immunoblotting, with the addition of 20 mM N-ethylmaleimide followed by brief sonication and centrifugation at 2,000 x g for 5 min. Protein concentration was determined using Bradford assay (Bio-Rad). 50 μ L anti-GFP beads were added to 1 mg total protein diluted in a total volume of 600 μ L RIPA buffer. Lysates were incubated for 1 h at 4 °C with end over end rotation. Cell lysates were applied to μ -columns equilibrated with 250 μ L RIPA buffer. Columns were washed 4 times with 1 mL 0.1% SDS/PBS. Bound proteins were eluted by applying 50 μ L pre-heated (95 °C) 1x SDS sample buffer. Input and eluates were resolved on NuPAGE 4-12% gradient gels in MOPS running buffer and transferred to nitrocellulose membranes. Membranes were probed with antibodies against GFP or ubiquitin-K48.

Native-PAGE analysis

Tet-TauRD-Y* cells were plated in 12-well plates and transfected with VCP variants using Lipofectamine 2000 for 2 days. Cells were then lysed in 50 μ L 0.5% TritonX-100/PBS supplemented with protease inhibitor cocktail and benzonase for 1 h on ice. Lysates were centrifuged at 10,000 x g for 2 min and supernatant was collected. Protein concentration in the supernatant was determined using Bradford assay and normalized in all samples before adding 2x native sample buffer (40 % glycerol, 240 mM Tris pH 6.8, 0.04 % bromophenol blue). Samples were analyzed on Novex Value 4 to 12% Tris-glycine gels (Thermo) using 20 mM Tris

200 mM Glycine buffer at pH 8.4. Proteins were transferred to nitrocellulose membrane in Tris-glycine buffer, blocked in 5% low-fat dry milk and co-incubated with primary followed by fluorescent secondary antibodies. Fluorescent signal was detected on an Odyssey Fc imager (LI-COR).

TauRD-Y seeding assay

TauRD-Y* cells were treated with 2 μ M NMS, 10 μ M VER or 50 nM epoxomicin for 24 h or 0.5 μ M MLN for 12 h, or with DMSO as control and lysed on ice in Triton buffer supplemented with protease inhibitor cocktail and benzonase for 20 min. The amount of TauRD-Y across the samples was normalized by quantifying TauRD-Y by immunoblotting using anti-GFP antibody and anti-GAPDH antibody as loading control. Lysates containing equal amounts of TauRD-Y were combined with Opti-MEM and Lipofectamine 3000, incubated for 20 min at RT and added to FRET biosensor cells. 24 h later, cells were harvested with trypsin, washed with PBS and analyzed on an Attune NxT flow cytometer (Imaging Facility, MPI Biochemistry). mTurquoise2 and FRET fluorescence signals were measured by exciting cells with a 405 nm laser and collecting fluorescent signal with 440/50 and 530/30 filters, respectively. To measure the YFP fluorescence signal, cells were excited with a 488 nm laser and emission was collected with a 530/30 filter. For each sample 50,000 single cells were evaluated. Data was processed using FlowJo v10.7.1 software (FlowJo LLC). After gating single cells, an additional gate was introduced to exclude cells that generate a false-positive signal in the FRET channel due to excitation at 405 nm⁸³. A FRET positive gate was drawn by plotting the FRET fluorescence signal versus the mTurquoise2 fluorescence signal using unseeded cells as reference.

Size exclusion chromatography of cell lysates

TauRD-Y* cells that had been treated for 24 h with DMSO or 2 μ M NMS were analyzed. Untreated TauRD-Y cells were analyzed as control. Cells were lysed as described in the section Seeding assay. Lysates were clarified by centrifugation at 1,000 x g for 5 min at 4 °C and filtered with a PVDF 0.22 μ m filter (Millex). The total protein amount of the lysates was determined by Bradford assay (Bio-Rad). 3 mg total protein was loaded on a Superose 6 HR10/30 (GE Healthcare) column equilibrated with PBS. The individual fractions separated by size exclusion chromatography were analyzed and quantified by immunoblotting using anti-GFP antibody. TauRD-Y species were detected in the void volume (HMW) and low molecular weight (LMW) fractions. Corresponding fractions were pooled and analyzed by immunoblotting using anti-GFP antibody. Seeding experiments were performed as described above, using 0.5 ng TauRD-Y from HMW and LMW fractions.

Statistical analysis

Statistical analysis was performed in Excel, Origin 2019b or GraphPad Prism 7 on data acquired from at least three independent experiments. Matched samples were compared using two-tailed Student's paired t-test. For multiple comparisons, one-way ANOVA followed by a Tukey post hoc test was used.

Data availability

All data supporting the findings of this study are included in the manuscript and the Supplemental Information, additional data that support the findings of this study are available from the corresponding author upon reasonable request. The mass spectrometry proteomics data associated to Fig. 2a have been deposited to the ProteomeXchange Consortium via the PRIDE⁸⁴

891 partner repository (<https://www.ebi.ac.uk/pride/archive/>) with the dataset identifier PXD023400.
892 This PRIDE entry additionally contains analyses that are not a part of this study.

893 **References**

- 894 1 Goedert, M., Eisenberg, D. S. & Crowther, R. A. Propagation of Tau aggregates and
895 neurodegeneration. *Annu Rev Neurosci* **40**, 189-210 (2017).
- 896 2 Strang, K. H., Golde, T. E. & Giasson, B. I. MAPT mutations, tauopathy, and mechanisms of
897 neurodegeneration. *Laboratory Investigation* **99**, 912-928 (2019).
- 898 3 Lewis, J. *et al.* Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice
899 expressing mutant (P301L) Tau protein. *Nat Genet* **25**, 402-405 (2000).
- 900 4 Allen, B. *et al.* Abundant Tau filaments and nonapoptotic neurodegeneration in transgenic mice
901 expressing human P301S Tau protein. *J Neurosci* **22**, 9340-9351 (2002).
- 902 5 Jucker, M. & Walker, L. C. Propagation and spread of pathogenic protein assemblies in
903 neurodegenerative diseases. *Nat Neurosci* **21**, 1341-1349 (2018).
- 904 6 Vaquer-Alicea, J. & Diamond, M. I. Propagation of protein aggregation in neurodegenerative
905 diseases. *Annual review of biochemistry* **88**, 785-810 (2019).
- 906 7 DeVos, S. L. *et al.* Tau reduction prevents neuronal loss and reverses pathological Tau deposition
907 and seeding in mice with tauopathy. *Sci Transl Med* **9**, 374 (2017).
- 908 8 Polydoro, M. *et al.* Reversal of neurofibrillary tangles and Tau-associated phenotype in the
909 rTgTauEC model of early Alzheimer's disease. *J Neurosci* **33**, 13300-13311 (2013).
- 910 9 Doyle, S. M., Genest, O. & Wickner, S. Protein rescue from aggregates by powerful molecular
911 chaperone machines. *Nat Rev Mol Cell Biol* **14**, 617-629 (2013).
- 912 10 Mogk, A., Bukau, B. & Kampina, H. H. Cellular handling of protein aggregates by disaggregation
913 machines. *Mol Cell* **69**, 214-226 (2018).
- 914 11 Nillegoda, N. B., Wentink, A. S. & Bukau, B. Protein disaggregation in multicellular organisms.
915 *Trends Biochem Sci* **43**, 285-300 (2018).
- 916 12 Faust, O. *et al.* HSP40 proteins use class-specific regulation to drive HSP70 functional diversity.
917 *Nature* **587**, 489-494 (2020).
- 918 13 Wentink, A. S. *et al.* Molecular dissection of amyloid disaggregation by human HSP70. *Nature*
919 **587**, 483-488 (2020).
- 920 14 Shorter, J. The mammalian disaggregase machinery: Hsp110 synergizes with Hsp70 and Hsp40 to
921 catalyze protein disaggregation and reactivation in a cell-free system. *PLoS One* **6**, e26319,
922 (2011).
- 923 15 Nachman, E. *et al.* Disassembly of Tau fibrils by the human Hsp70 disaggregation machinery
924 generates small seeding-competent species. *J Biol Chem* **295**, 9676-9690 (2020).
- 925 16 Schneider, M. M. *et al.* The Hsc70 disaggregation machinery removes monomer units directly
926 from α -synuclein fibril ends. *Nature Communications* **12**, 5999 (2021).
- 927 17 Gao, X. *et al.* Human Hsp70 disaggregase reverses Parkinson's-linked alpha-Synuclein amyloid
928 fibrils. *Mol Cell* **59**, 781-793 (2015).
- 929 18 Bodnar, N. O. & Rapoport, T. A. Molecular mechanism of substrate processing by the Cdc48
930 ATPase complex. *Cell* **169**, 722-735 (2017).
- 931 19 Ji, Z. *et al.* Translocation of polyubiquitinated protein substrates by the hexameric Cdc48
932 ATPase. *Mol Cell*, **82**(3), 570-584 (2021).
- 933 20 Darwich, N. F. *et al.* Autosomal dominant VCP hypomorph mutation impairs disaggregation of
934 PHF-tau. *Science*, eaay8826 (2020).
- 935 21 Kobayashi, T., Manno, A. & Kakizuka, A. Involvement of valosin-containing protein (VCP)/p97 in
936 the formation and clearance of abnormal protein aggregates. *Genes Cells* **12**, 889-901 (2007).
- 937 22 Gwon, Y. *et al.* Ubiquitination of G3BP1 mediates stress granule disassembly in a context-specific
938 manner. *Science* **372**, eabf6548 (2021).

939 23 Buchan, J. R., Kolaitis, R.-M., Taylor, J. P. & Parker, R. Eukaryotic stress granules are cleared by
940 autophagy and Cdc48/VCP function. *Cell* **153**, 1461-1474 (2013).

941 24 van den Boom, J. & Meyer, H. VCP/p97-mediated unfolding as a principle in protein homeostasis
942 and signaling. *Mol Cell* **69**, 182-194 (2018).

943 25 Olszewski, M. M., Williams, C., Dong, K. C. & Martin, A. The Cdc48 unfoldase prepares well-
944 folded protein substrates for degradation by the 26S proteasome. *Communications Biology* **2**, 29
945 (2019).

946 26 Meyer, H. & Wehl, C. C. The VCP/p97 system at a glance: connecting cellular function to disease
947 pathogenesis. *Journal of Cell Science* **127**, 3877 (2014).

948 27 Johnson, J. O. *et al.* Exome sequencing reveals VCP mutations as a cause of familial ALS. *Neuron*
949 **68**, 857-864 (2010).

950 28 Schroder, R. *et al.* Mutant valosin-containing protein causes a novel type of frontotemporal
951 dementia. *Annals of neurology* **57**, 457-461 (2005).

952 29 Watts, G. D. *et al.* Inclusion body myopathy associated with Paget disease of bone and
953 frontotemporal dementia is caused by mutant valosin-containing protein. *Nat Genet* **36**, 377-
954 381 (2004).

955 30 Blythe, E. E., Olson, K. C., Chau, V. & Deshaies, R. J. Ubiquitin- and ATP-dependent unfoldase
956 activity of P97/VCP*NPLOC4*UFD1L is enhanced by a mutation that causes multisystem
957 proteinopathy. *Proc Natl Acad Sci U S A* **114**, E4380-E4388 (2017).

958 31 Manno, A., Noguchi, M., Fukushi, J., Motohashi, Y. & Kakizuka, A. Enhanced ATPase activities as
959 a primary defect of mutant valosin-containing proteins that cause inclusion body myopathy
960 associated with Paget disease of bone and frontotemporal dementia. *Genes Cells* **15**, 911-922
961 (2010).

962 32 Blythe, E. E., Gates, S. N., Deshaies, R. J. & Martin, A. Multisystem Proteinopathy mutations in
963 VCP/p97 increase NPLOC4-UFD1L binding and substrate processing. *Structure* **27**, 1820-1829
964 (2019).

965 33 Ritz, D. *et al.* Endolysosomal sorting of ubiquitylated caveolin-1 is regulated by VCP and UBXD1
966 and impaired by VCP disease mutations. *Nature Cell Biology* **13**, 1116-1123 (2011).

967 34 Tresse, E. *et al.* VCP/p97 is essential for maturation of ubiquitin-containing autophagosomes and
968 this function is impaired by mutations that cause IBMPFD. *Autophagy* **6**, 217-227 (2010).

969 35 Barghorn, S., Davies, P. & Mandelkow, E. Tau paired helical filaments from Alzheimer's disease
970 brain and assembled in vitro are based on beta-structure in the core domain. *Biochemistry* **43**,
971 1694-1703 (2004).

972 36 Crowther, T., Goedert, M. & Wischik, C. M. The repeat region of microtubule-associated protein
973 Tau forms part of the core of the paired helical filament of Alzheimer's disease. *Ann Med* **21**,
974 127-132 (1989).

975 37 Sanders, D. W. *et al.* Distinct Tau prion strains propagate in cells and mice and define different
976 tauopathies. *Neuron* **82**, 1271-1288 (2014).

977 38 Frost, B., Ollesch, J., Wille, H. & Diamond, M. I. Conformational diversity of wild-type Tau fibrils
978 specified by templated conformation change. *J Biol Chem* **284**, 3546-3551 (2009).

979 39 Schmued, L. *et al.* Introducing Amylo-Glo, a novel fluorescent amyloid specific histochemical
980 tracer especially suited for multiple labeling and large scale quantification studies. *Journal of*
981 *Neuroscience Methods* **209**, 120-126 (2012).

982 40 Falcon, B. *et al.* Structures of filaments from Pick's disease reveal a novel Tau protein fold.
983 *Nature* **561**, 137-140 (2018).

984 41 Falcon, B. *et al.* Novel Tau filament fold in chronic traumatic encephalopathy encloses
985 hydrophobic molecules. *Nature* **568**, 420-423 (2019).

986 42 Fitzpatrick, A. W. P. *et al.* Cryo-EM structures of Tau filaments from Alzheimer's disease. *Nature*
987 **547**, 185-190 (2017).

988 43 Spillantini, M. G. *et al.* Familial multiple system tauopathy with presenile dementia: a disease
989 with abundant neuronal and glial Tau filaments. *Proc Natl Acad Sci U S A* **94**, 4113-4118 (1997).

990 44 Zhang, W. *et al.* Novel Tau filament fold in corticobasal degeneration. *Nature* **580**, 283-287
991 (2020).

992 45 Braak, H., Thal, D. R., Ghebremedhin, E. & Del Tredici, K. Stages of the pathologic process in
993 Alzheimer disease: age categories from 1 to 100 years. *J Neuropathol Exp Neurol* **70**, 960-969
994 (2011).

995 46 Goedert, M., Jakes, R. & Vanmechelen, E. Monoclonal antibody AT8 recognises Tau protein
996 phosphorylated at both serine 202 and threonine 205. *Neurosci Lett* **189**, 167-169 (1995).

997 47 Petrucelli, L. *et al.* CHIP and Hsp70 regulate Tau ubiquitination, degradation and aggregation.
998 *Human Molecular Genetics* **13**, 703-714 (2004).

999 48 Hyun, D. H., Lee, M., Halliwell, B. & Jenner, P. Proteasomal inhibition causes the formation of
1000 protein aggregates containing a wide range of proteins, including nitrated proteins. *Journal of*
1001 *neurochemistry* **86**, 363-373 (2003).

1002 49 Hjerpe, R. *et al.* UBQLN2 mediates autophagy-independent protein aggregate clearance by the
1003 proteasome. *Cell* **166**, 935-949 (2016).

1004 50 Twomey, E. C. *et al.* Substrate processing by the Cdc48 ATPase complex is initiated by ubiquitin
1005 unfolding. *Science* **365**, eaax1033 (2019).

1006 51 Magnaghi, P. *et al.* Covalent and allosteric inhibitors of the ATPase VCP/p97 induce cancer cell
1007 death. *Nat Chem Biol* **9**, 548-556 (2013).

1008 52 Zhou, H.-J. *et al.* Discovery of a first-in-class, potent, selective, and orally bioavailable inhibitor of
1009 the p97 AAA ATPase (CB-5083). *Journal of Medicinal Chemistry* **58**, 9480-9497 (2015).

1010 53 Bäuerlein, F. J. B. *et al.* In situ architecture and cellular interactions of polyQ inclusions. *Cell* **171**,
1011 179-187 (2017).

1012 54 Trinkaus, V. A. *et al.* In situ architecture of neuronal α -Synuclein inclusions. *Nat Commun* **12**,
1013 2110 (2021).

1014 55 Hyer, M. L. *et al.* A small-molecule inhibitor of the ubiquitin activating enzyme for cancer
1015 treatment. *Nat Med* **24**, 186-193 (2018).

1016 56 Gupta, R. *et al.* Firefly luciferase mutants as sensors of proteome stress. *Nat Methods* **8**, 879-884
1017 (2011).

1018 57 Schlecht, R. *et al.* Functional analysis of Hsp70 inhibitors. *PLoS One* **8**, e78443-e78443 (2013).

1019 58 Forman, M. S. *et al.* Novel ubiquitin neuropathology in frontotemporal dementia with valosin-
1020 containing protein gene mutations. *J Neuropathol Exp Neurol* **65**, 571-581 (2006).

1021 59 Weihl, C. C., Dalal, S., Pestronk, A. & Hanson, P. I. Inclusion body myopathy-associated
1022 mutations in p97/VCP impair endoplasmic reticulum-associated degradation. *Human Molecular*
1023 *Genetics* **15**, 189-199 (2005).

1024 60 Dalal, S., Rosser, M. F., Cyr, D. M. & Hanson, P. I. Distinct roles for the AAA ATPases NSF and p97
1025 in the secretory pathway. *Mol Biol Cell* **15**, 637-648 (2004).

1026 61 Zhu, J. *et al.* VCP protects neurons from proteopathic seeding. *BioRxiv*,
1027 doi.org/10.1101/2021.07.12.452081 (2021).

1028 62 Yuste-Checa, P. *et al.* The extracellular chaperone Clusterin enhances Tau aggregate seeding in a
1029 cellular model. *Nature Communications* **12**, 4863 (2021).

1030 63 Erives, A. J. & Fassler, J. S. Metabolic and chaperone gene loss marks the origin of animals:
1031 evidence for Hsp104 and Hsp78 chaperones sharing mitochondrial enzymes as clients. *PLoS One*
1032 **10**, e0117192-e0117192 (2015).

- 64 Sontag, E. M., Samant, R. S. & Frydman, J. Mechanisms and functions of spatial protein quality control. *Annual review of biochemistry* **86**, 97-122 (2017).
- 65 Cliffe, R. *et al.* Filamentous aggregates are fragmented by the proteasome holoenzyme. *Cell Rep* **26**, 2140-2149 (2019).
- 66 Higashiyama, H. *et al.* Identification of ter94, Drosophila VCP, as a modulator of polyglutamine-induced neurodegeneration. *Cell Death Differ* **9**, 264-273 (2002).
- 67 Khosravi, B. *et al.* Cell-to-cell transmission of C9orf72 poly-(Gly-Ala) triggers key features of ALS/FTD. *EMBO J* **39**, e102811 (2020).
- 68 Jackrel, M. E. *et al.* Potentiated Hsp104 variants antagonize diverse proteotoxic misfolding events. *Cell* **156**, 170-182 (2014).
- 69 Shorter, J. Engineering therapeutic protein disaggregases. *Mol Biol Cell* **27**, 1556-1560 (2016).
- 70 VerPlank, J. J. S., Tyrkalska, S. D., Fleming, A., Rubinsztein, D. C. & Goldberg, A. L. cGMP via PKG activates 26S proteasomes and enhances degradation of proteins, including ones that cause neurodegenerative diseases. *Proc Natl Acad Sci U S A* **117**, 14220-14230 (2020).
- 71 Gu, X. *et al.* SAMTOR is an S-adenosylmethionine sensor for the mTORC1 pathway. *Science* **358**, 813-818 (2017).
- 72 Schmittgen, T. D. & Livak, K. J. Analyzing real-time PCR data by the comparative C(T) method. *Nat Protoc* **3**, 1101-1108 (2008).
- 73 Guo, Q. *et al.* In situ structure of neuronal C9orf72 poly-GA aggregates reveals proteasome recruitment. *Cell* **172**, 696-705 (2018).
- 74 Rigort, A. *et al.* Focused ion beam micromachining of eukaryotic cells for cryoelectron tomography. *Proc Natl Acad Sci U S A* **109**, 4449-4454 (2012).
- 75 Mastronarde, D. N. Automated electron microscope tomography using robust prediction of specimen movements. *J Struct Biol* **152**, 36-51 (2005).
- 76 Fukuda, Y., Laugks, U., Lučić, V., Baumeister, W. & Danev, R. Electron cryotomography of vitrified cells with a Volta phase plate. *J Struct Biol* **190**, 143-154 (2015).
- 77 Li, X. *et al.* Electron counting and beam-induced motion correction enable near-atomic-resolution single-particle cryo-EM. *Nat Methods* **10**, 584-590 (2013).
- 78 Kremer, J. R., Mastronarde, D. N. & McIntosh, J. R. Computer visualization of three-dimensional image data using IMOD. *J Struct Biol* **116**, 71-76 (1996).
- 79 Rigort, A. *et al.* Automated segmentation of electron tomograms for a quantitative description of actin filament networks. *J Struct Biol* **177**, 135-144 (2012).
- 80 Martinez-Sanchez, A., Garcia, I., Asano, S., Lucic, V. & Fernandez, J. J. Robust membrane detection based on tensor voting for electron tomography. *J Struct Biol* **186**, 49-61 (2014).
- 81 Ong, S. E. *et al.* Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. *Mol Cell Proteomics* **1**, 376-386 (2002).
- 82 Wiśniewski, J. R., Zielinska, D. F. & Mann, M. Comparison of ultrafiltration units for proteomic and N-glycoproteomic analysis by the filter-aided sample preparation method. *Anal Biochem* **410**, 307-309 (2011).
- 83 Banning, C. *et al.* A flow cytometry-based FRET assay to identify and analyse protein-protein interactions in living cells. *PLoS One* **5**, e9344 (2010).
- 84 Perez-Riverol, Y. *et al.* The PRIDE database and related tools and resources in 2019: improving support for quantification data. *Nucleic Acids Res* **47**, D442-d450 (2019).

Acknowledgements

We thank Ralf Zenke, Markus Oster, Giovanni Cardone and Martin Spitaler from the MPIB Imaging Facility for assistance with confocal microscopy, image analysis and flow cytometry, and Albert Ries for assistance with mass spectrometry. We acknowledge Gopal Jayaraj for generation of the Fluc-GFP cell line and Alonso Izzat Carvajal Alvarez for help with native PAGE analysis. The research leading to these results has received funding from the European Commission under Grant FP7 GA ERC- 2012-SyG_318987–ToPAG (I.S., R.K., P.Y.-C., I.D., R.F.-B., F.U.H. and M.S.H.), Marie Skłodowska-Curie grant (agreement no. 749370) (S.G.), the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany's Excellence Strategy within the framework of the Munich Cluster for Systems Neurology (EXC 2145 SyNergy – ID 390857198) (V.A.T., F.U.H. and M.S.H.) and MBExC (EXC 2067/1 — ID 390729940) (R.F.-B.), as well as by the joint efforts of The Michael J. Fox Foundation for Parkinson's Research (MJFF) and the Aligning Science Across Parkinson's (ASAP) initiative. MJFF administers the grant ASAP-000282 on behalf of ASAP and itself. M.S.H. acknowledges the funding from Alzheimer Nederland (Grant Number WE.03-2020-12).

Author contributions

I.S. designed and performed most experiments. P.Y. performed seeding experiments. M.D.P. performed neuronal cultures. Q.G. and V.A.T. carried out cryo-electron tomography of Tau aggregates in TauRD-Y* cells and primary neurons, respectively. R.K. performed mass spectrometry analysis. S.G. helped with initial experiments and quantified inclusion size. H.H. performed mRNA analysis. I.D. supervised experiments with neuronal cultures. R.F.B. and W.B. supervised cryo-electron tomography experiments. D.W.S. and M.I.D. provided cell lines,

1100 protocols and contributed to the interactome analysis. F.U.H. and M.S.H. initiated and
1101 supervised the project and wrote the manuscript with input from I.S. and the other authors.

1102
1103 **Competing interests**

1104 Authors declare no competing interests.